|
2021
|
Invention
|
Radiolabelled alpha-v beta-3 and/or alpha-v beta-5 integrins antagonist for use as theragnostic a... |
|
|
Invention
|
Methods for synthesis of radionuclide complex.
The present disclosure relates to the synthesis o... |
|
|
Invention
|
Methods for radiolabelling psma binding ligands and their kits. The present disclosure relates to... |
|
|
Invention
|
Methods for radiolabeling psma binding ligands and their kits. The present invention relates to m... |
|
2020
|
Invention
|
Radiolabelled grpr-antagonist for use as theragnostic. The present disclosure relates to gastrin-... |
|
|
Invention
|
Methods for radiolabelling grpr antagonists and their kits. The present invention relates to meth... |
|
|
Invention
|
Stable, concentrated radiopharmaceutical composition. The present disclosure relates to radionucl... |
|
|
Invention
|
Prostate specific membrane antigen (psma) ligands and uses thereof.
The present disclosure relat... |
|
|
Invention
|
Prostate specific membrane antigen (psma) ligands and uses thereof. The present disclosure relate... |
|
2019
|
Invention
|
Combination therapy.
The present invention relates to combination therapies of radiolabelled som... |
|
|
Invention
|
Combination therapy. The present invention relates to combination therapies of radiolabelled soma... |
|
|
Invention
|
Method of treatment of neuroendocrine tumors. The present invention relates to methods of treatin... |
|
2018
|
Invention
|
Methods for synthesis of radionuclide complex. The present disclosure relates to the synthesis of... |
|
|
Invention
|
Stable, concentrated radionuclide complex solutions. The present invention relates to radionuclid... |
